Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Characterization of disease course and remission in early seropositive rheumatoid arthritis: Results from the TACERA longitudinal cohort study

RA-MAP Consortium, Brian Tom
doi: https://doi.org/10.1101/2020.03.08.20028142
1United Kingdom
Brian Tom
2MRC Biostatistics Unit, University of Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: brian.tom@mrc-bsu.cam.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background To characterize disease course and remission in a longitudinal observational study of newly diagnosed, initially treatment naïve patients with seropositive rheumatoid arthritis (RA).

Methods Patients with early untreated seropositive RA were recruited from 28 UK centres. Multiple clinical and laboratory measures were collected every 3 months for up to 18 months. Disease activity was measured using DAS28-CRP and SDAI. Logistic regression models examined clinical predictors of 6-month remission and latent class mixed models characterized disease course.

Results We enrolled 275 patients of whom 267 met full eligibility and provided baseline data. According to SDAI definition, 24.3% attained 6-month remission. Lower baseline HAQ and SDAI predicted 6-month remission (p=0.002 and 0.021). Alcohol intake and baseline prescribing of methotrexate with a second DMARD (versus monotherapy without glucocorticoids) were also predictive. Three distinct SDAI trajectory subpopulations emerged; corresponding to an Inadequate Responder group (6.5%), and Higher and Lower Baseline Activity Responder groups (22.4% and 71.1%). Baseline HAQ and SF-36 MCS only distinguished these groups. Additionally a number of baseline clinical predictors correlated with disease activity severity within subpopulations. Beneficial effects of alcohol intake were found across subpopulations.

Conclusions Three distinct disease trajectory subpopulations were identified. Differential effects of functional and mental well-being, alcohol consumption and baseline RA medication prescribing on disease activity severity were found across subpopulations. Heterogeneity across trajectories cannot be fully explained by baseline clinical predictors. Biological markers collected early in disease course (within 6 months) may help patient management and to better target existing and novel therapies.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ISRCTN28793839

Clinical Protocols

http://www.isrctn.com/ISRCTN28793839

Funding Statement

This study was funded by the MRC/ABPI Inflammation and Immunology Initiative Grant (MRC reference numbers: G1001516 and G1001518). Dr Brian Tom is supported by the UK Medical Research Council (Unit Programme number MC_UP_1302/3 and MC_UU_00002/2).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data are available through the RA-MAP Sample and Data Access Committee. Contact: Dr Dennis Lendrem (dennis.lendrem{at}ncl.ac.uk)

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 12, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of disease course and remission in early seropositive rheumatoid arthritis: Results from the TACERA longitudinal cohort study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Characterization of disease course and remission in early seropositive rheumatoid arthritis: Results from the TACERA longitudinal cohort study
RA-MAP Consortium, Brian Tom
medRxiv 2020.03.08.20028142; doi: https://doi.org/10.1101/2020.03.08.20028142
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Characterization of disease course and remission in early seropositive rheumatoid arthritis: Results from the TACERA longitudinal cohort study
RA-MAP Consortium, Brian Tom
medRxiv 2020.03.08.20028142; doi: https://doi.org/10.1101/2020.03.08.20028142

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Rheumatology
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (423)
  • Anesthesia (97)
  • Cardiovascular Medicine (902)
  • Dentistry and Oral Medicine (172)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (408)
  • Epidemiology (8810)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1871)
  • Geriatric Medicine (179)
  • Health Economics (389)
  • Health Informatics (1294)
  • Health Policy (644)
  • Health Systems and Quality Improvement (495)
  • Hematology (207)
  • HIV/AIDS (397)
  • Infectious Diseases (except HIV/AIDS) (10593)
  • Intensive Care and Critical Care Medicine (565)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1770)
  • Nursing (105)
  • Nutrition (267)
  • Obstetrics and Gynecology (344)
  • Occupational and Environmental Health (461)
  • Oncology (968)
  • Ophthalmology (285)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (265)
  • Pediatrics (560)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1847)
  • Public and Global Health (3998)
  • Radiology and Imaging (657)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (538)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (167)
  • Surgery (199)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)